PBF-680

Pamplona, Spain – Palobiofarma S.L. is pleased to announce the “last patient last visit” of the Phase II trial investigating the safety and preliminary efficacy of PBF-680 in moderate to severe COPD patients. The trial has recruited 104 patients in 12 hospitals in Spain. The primary endpoint of the study is the change from baseline in blood eosinophils, which correlates with the risk of exacerbation in this population. The PBF-680 project has received the support of the EIC accelerator program, which has been fundamental to secure the financing needed for the completion of the Phase II trial in COPD. Palobiofarma is now generating first top line results of this study facing the upcoming Bio-USA conference in San Diego to continue licensing discussions with pharmaceutical companies interested in developing novel therapies for severe respiratory diseases. “We are extremely happy with the conclusion of the trial and look forward to generating the first results,” stated Julio Castro, PhD, Chief Executive Officer of Palobiofarma S.L. “Positive clinical results would allow to advance the clinical development of PBF-680 bringing this novel disease-modifying treatment closer to the patients. We are extremely grateful for the European support received through the EIC accelerator program”. PBF-680 is a novel and potent oral adenosine A1 antagonist discovered by Palobiofarma. The compound is potentially a first in class and has demonstrated to be safe and effective in previous clinical trials in asthmatics, where the administration of the compound produced a pronounced, statistically significant reduction of blood eosinophils, along with significant improvements in lung function parameters. Chronic obstructive pulmonary disease (COPD) is a type of progressive lung disease characterized by long-term respiratory symptoms, and bronchoconstriction which results in airflow limitation. COPD represents a high unmet medical need. As of 2022, COPD affected over 200 million people and caused 3.2 million deaths. The number of deaths is projected to increase further because of continued exposure to risk factors and an aging population. In the United States in 2021 the economic cost was put at US$50.1 billion and projected to rise to US$60 billion in 2025. Current treatment for severe COPD includes triple therapy with LAMA, LABA and corticoids which, after a few months, show a clear decline in clinical benefit. For further information or media inquiries, please contact: Julio Castro jcastro@palobiofarma.com or visit www.palobiofarma.com About Palobiofarma S.L. Palobiofarma S.L., is a biopharmaceutical company committed to discovering and developing first-in-class therapeutics based on the modulation of the adenosinergic pathways. Palobiofarma owns a robust and diversified pipeline, with six compounds in clinical development targeting diseases of high unmet medical needs. The company is participated by two important Spanish VCs as Inveready and Sodena. About PBF-680 PBF-680 is a novel, potent and selective adenosine A1 receptor antagonist discovered and patented by Palobiofarma. PBF-680 is in Phase 2 clinical development for the treatment of asthma and COPD.